Efficacy of duloxetine for the treatment of generalized anxiety disorder: Implications for primary care physicians

Primary Care Companion to the Journal of Clinical Psychiatry

Volumn 9, Issue 2, 2007, Pages 100-107

  Koponen, Hannu ^a   Allgulander, Christer ^b   Erickson, Janelle ^c   Dunayevich, Eduardo ^c,f   Pritchett, Yili ^c,g   Detke, Michael J ^c,d,e   Ball, Susan G ^c,d   Russell, James M ^c  

^a UNIVERSITY OF EASTERN FINLAND   (Finland)

^b KAROLINSKA INSTITUTE   (Sweden)

^c ELI LILLY AND COMPANY   (United States)

^d INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e HARVARD MEDICAL SCHOOL   (United States)

^f Orexigen Therapeutics   (United States)

^g ABBOTT LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DULOXETINE; NORADRENALIN UPTAKE INHIBITOR; PLACEBO; SEROTONIN UPTAKE INHIBITOR;

ADULT; ANXIETY; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; GENERALIZED ANXIETY DISORDER; HAMILTON ANXIETY SCALE; HEADACHE; HUMAN; HYPERHIDROSIS; INSOMNIA; IRRITABILITY; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NAUSEA; PARESTHESIA; PRIMARY MEDICAL CARE; RACE DIFFERENCE; RANDOMIZED CONTROLLED TRIAL; REMISSION; SIDE EFFECT; TREATMENT RESPONSE; TREMOR;

EID: 34147180827     PISSN: 15235998     EISSN: 1555211X     Source Type: Journal    
DOI: 10.4088/pcc.v09n0203     Document Type: Article

References (38)

1. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition. Washington, DC: American Psychiatric Press, Inc; 1994
2. Rickels K, Rynn MA. What is generalized anxiety disorder? J Clin Psychiatry 2001;62:4-11
3. Hoehn-Saric R. Psychic and somatic anxiety: worries, somatic symptoms and physiological changes. Acta Psychiatr Scand Suppl 1998;393:32-38
4. Becker ES, Goodwin R, Holting C, et al. Content of worry in the community: what do people with generalized anxiety disorder or other disorders worry about? J Nerv Ment Dis 2003;191:688-691
5. Wittchen HU, Kessler RC, Beesdo K, et al. Generalized anxiety and depression in primary care: prevalence, recognition, and management. J Clin Psychiatry 2002;63:24-34
6. Ansseau M, Fischler B, Dietrick M, et al. Prevalence and impact of generalized anxiety disorder and major depression in primary care in Belgium and Luxemburg: the GADIS study. Eur Psychiatry 2005;20:229-235
7. Hoehn-Saric R. Generalized anxiety disorder in medical practice. Prim Psychiatry 2005;12:30-34
8. Nutt DJ, Ballenger JC, Sheehan D, et al. Generalized anxiety disorder: comorbidity, comparative biology and treatment. Int J Neuropsychopharmacol 2002;5:315-325
9. Goodman WK. Selecting pharmacotherapy for generalized anxiety disorder. J Clin Psychiatry 2004;65(suppl 13):8-13
10. Pollack MH. Optimizing pharmacotherapy of generalized anxiety disorder to achieve remission. J Clin Psychiatry 2001;62:20-25
11. Allgulander C, Bandelow B, Hollander E, et al. WCA recommendations for the long-term treatment of generalized anxiety disorder. CNS Spectrums 2004;8(suppl 1):53-61
12. Ballenger JC, Davidson JR, Lecrubier Y, et al. Consensus statement on generalized anxiety disorder from the International Consensus Group on Depression and Anxiety. J Clin Psychiatry 2001;62:53-58
13. Detke MJ, Lu Y, Goldstein DJ, et al. Duloxetine, 60 mg once daily, for major depressive disorder: a randomized double-blind placebo-controlled trial. J Clin Psychiatry 2002;63:308-315
14. Goldstein DJ, Lu Y, Detke MJ, et al. Duloxetine vs placebo in patients with painful diabetic neuropathy. Pain 2005;116:109-118
15. Hamilton M. Development of a rating scale for primary depressive illness. Br J Soc Clin Psychol 1967;6:278-296
16. Dunner DL, Goldstein DJ, Mallinckrodt C, et al. Duloxetine in treatment of anxiety symptoms associated with depression. Depress Anxiety 2003;18:53-61
17. Trolesen KB, Nielson EO, Mirza NR. Chronic treatment with duloxetine is necessary for an anxiolytic-like response in the mouse zero maze: the role of the serotonin transporter. Psychopharmacology 2005;181:741-750
18. Sheehan DV, Lecrubier Y, Sheehan KH, et al. The MINI-International Neuropsychiatric Interview for DSM-IV. J Clin Psychiatry 1998;59(suppl 20):34-57
19. Shear MK, Vander Bilt J, Rucci P, et al. Reliability and validity of a structured interview guide for the Hamilton Anxiety Rating Scale (SIGH-A). Depress Anxiety 2001;13:166-178
20. Lipsitz J, Kobak K, Feiger A, et al. The Rater Applied Performance Scale: development and reliability. Psychiatry Res 2004;127:147-155
21. Lipman RS, Covi L, Downing RW, et al. Pharmacotherapy of anxiety and depression: rationale and study design. Psychopharmacol Bull 1981;17:91-94
22. Raskin A, Schulterbrandt J, Reatig N, et al. Replication of factors of psychopathology in interview, ward behavior and self-report ratings of hospitalized depressives. J Nerv Ment Dis 1969;148:87-98
23. World Medical Association. Declaration of Helsinki: Ethical Principles for Medical Research Involving Human Subjects. First adopted in 1964; most recent revision in 2000. Available at: http://www.wma.net/e/policy/b3.htm. Accessibility verified January 12, 2007
24. Hamilton M. The assessment of anxiety states by rating. Br J Med Psychol 1959;32:50-55
25. Zigmond AS, Snaith RP. The Hospital Anxiety and Depression Scale. Acta Psychiatr Scand 1983;67:361-370
26. Guy W. The clinician global severity and impression scales. ECDEU Assessment Manual for Psychopharmacology. US Dept Health, Education, and Welfare publication (ADM) 76-338. Rockville, Md: National Institute of Mental Health; 1976:218-222
27. Guy W. The patient's global impression and severity scale. ECDEU Assessment Manual for Psychopharmacology. US Dept Health, Education, and Welfare publication (ADM) 76-338. Rockville, Md: National Institute of Mental Health; 1976
28. Sheehan DV. The Anxiety Disease. New York, NY: Charles Scribner and Sons; 1983
29. DeLoach LJ, Higgins MS, Caplan AB, et al. The visual analog scale in the immediate post-operative period: intrasubject variability and correlation with a numeric scale. Anesth Analg 1998;86:102-106
30. Malllinckrodt CH, Kaiser CJ, Watkin JG, et al. The effect of correlation structure on treatment contrasts estimated from incomplete clinical trial data with likelihood-based repeated measures compared with the last observation carried forward ANOVA. Clin Trials 2004;1:477-489
31. Doyle AC, Pollack MH. Establishment of remission criteria for anxiety disorders. J Clin Psychiatry 2003;64(suppl 15):40-45
32. Rodriguez BF, Weisberg RB, Pagano ME, et al. Characteristics and predictors of full and partial recovery from generalized anxiety disorder in primary care patients. J Nerv Ment Dis 2006;194:91-97
33. Kessler RC, Chiu WT, Demler O, et al. Prevalence, severity, and comorbidity of 12-month DSM-IV disorders in the National Comorbidity Survey Replication. Arch Gen Psychiatry 2005;62:617-627
34. Wang PS, Berglund P, Kessler RC. Recent care of common mental disorders in the United States: prevalence and conformance with evidence-based recommendations. J Gen Intern Med 2000;15:284-292
35. Wang PS, Berglund P, Olfson M, et al. Failure and delay in initial treatment contact after first onset of mental disorders in the National Comorbidity Survey Replication. Arch Gen Psychiatry 2005;62:603-613
36. Spitzer RL, Williams JBW, Kroenke K, et al. Primary Care Evaluation of Mental Disorders (PRIME-MD). In: Rush AJ, Pincus HA, First MB, et al, eds. Handbook of Psychiatric Measures. Washington, DC: American Psychiatric Association; 2000:65-68
37. Spitzer RL, Williams JB, Kroenke K, et al. Utility of a new procedure for diagnosing mental disorders in primary care: the PRIME-MD 1000 study. JAMA 1994;272:1749-1756
38. Kessler RC, Wittchen HU. Patterns and correlates of generalized anxiety disorder in community samples. J Clin Psychiatry 2002;63(suppl 8):4-10